All In Biotech

BLA 761137 · Astellas

Padcev

Enfortumab Vedotin-Ejfv · Injection

NovelBreakthrough therapyAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 18, 2019

Approved uses

8

Original approval plus efficacy supplements

Registered trials

90

13 Phase 3, 49 recruiting

FAERS reports

7,851

6,925 serious, 1,561 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS SKIN REACTIONS • PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later. • Closely monitor patients for skin reactions. • Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions. • Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 ), and Adverse Reactions ( 6.1 )]. WARNING: SERIOUS SKIN REACTIONS See full prescribing information for complete boxed warning. • PADCEV can cause severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). •...

What it is approved for

From the label in effect Aug 4, 2026.

PADCEV ® , in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). PADCEV ® , in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). PADCEV, as a single agent, is indicated for the treatment of adult patients with la/mUC who: • have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or • are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated: • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1 ) • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). ( 1 ) • as a single agent for the treatment of adult patients with la/mUC who: ○ have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or ○ are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. ( 1 )

Mechanism: Enfortumab vedotin-ejfv is an ADC. The antibody is a human IgG1 kappa directed against Nectin-4, an adhesion protein located on the surface of cells. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggest that the anticancer activity of enfortumab vedotin-ejfv is due to the binding of the ADC to Nectin-4-expressing cells, followed by internalization of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic cleavage. Release of MMAE disrupts the microtubule network within the cell, subsequently...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 10, 2026 Supplement 37 · Efficacy · priority review LetterLabel
  • Nov 21, 2025 Supplement 32 · Efficacy · priority review LetterLabel
  • Dec 15, 2023 Supplement 24 · Efficacy · priority review LabelLetter
  • Dec 15, 2023 Supplement 25 · Efficacy · priority review LabelLetter
  • Apr 3, 2023 Supplement 18 · Efficacy · priority review Breakthrough therapyPatient Information SheetLetter
  • Jul 9, 2021 Supplement 8 · Efficacy · priority review LabelLetter
  • Jul 9, 2021 Supplement 6 · Efficacy · priority review LabelLetter
  • Dec 18, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
2 products under this application
  • PADCEV · ENFORTUMAB VEDOTIN-EJFV 20MG/VIAL · INJECTABLE, INJECTION · Prescription
  • PADCEV · ENFORTUMAB VEDOTIN-EJFV 30MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Enfortumab Vedotin" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash1,019
  • neuropathy peripheral909
  • malignant neoplasm progression893
  • diarrhoea503
  • pruritus467
  • death436
  • decreased appetite424
  • fatigue423
  • off label use362
  • alopecia324
  • skin disorder314
  • pyrexia313

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20172
20181
2020221
2021328
2022877
2023951
20241,165
20252,438
20261,868

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Padcev (Enfortumab Vedotin-Ejfv)

2024 spending

$9.4M

Beneficiaries

75

381 claims

Per beneficiary

$125,841

$3,616.71 per unit

View as table
YearSpending
2020$1,572,893
2021$1,634,736
2022$2,790,214
2023$4,437,952
2024$9,438,058

Part B: Padcev (Enfortumab Vedotin-Ejfv) · HCPCS J9177

2024 spending

$641M

Beneficiaries

5,839

50,610 claims

Per beneficiary

$109,818

2024 ASP limit $36.02 per unit

View as table
YearSpending
2020$63,345,400
2021$154,355,577
2022$189,323,880
2023$311,587,696
2024$641,224,462

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 65 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.